106%+ returns, 97% win rate: A fresh list of AI-picked stock is out NOW
ROCKVILLE, MD - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT), a company specializing in cell-engineering technologies for cell-based therapies, has filed its Form 10-K annual report for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC). The document, which details the company’s financial performance and operational highlights, is now accessible on the SEC’s website and MaxCyte’s investor relations page.
The Form 10-K filing provides investors with comprehensive information on MaxCyte’s business, including its financial statements and details about its ExPERT™ platform, a suite of products that supports the development of cell therapies. The platform encompasses a range of instruments, proprietary processing assemblies, and software protocols, backed by a significant intellectual property portfolio.
MaxCyte’s technology, which relies on Flow Electroporation®, is designed to meet the needs of the growing cell therapy market, from research and development to commercial production of advanced cell-based treatments. The company has emphasized its commitment to aiding partners in their efforts to revolutionize medical treatments through cell engineering.
The filing of the Form 10-K is a routine disclosure that publicly traded companies in the United States are required to submit annually to the SEC. It provides a detailed look at a company’s financial health, including audited financial statements, and is a critical document for investors and analysts in assessing a company’s performance and prospects.
MaxCyte has not disclosed any financial figures or specific performance metrics in the press release. Investors interested in MaxCyte’s detailed financial results and operational achievements for the year ended December 31, 2024, are encouraged to review the Form 10-K on the SEC’s website or on the company’s investor relations page.
This news article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.